Disc Medicine (IRON) risk factors, FY2025 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
2. 02We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future
3. 03future accounting pronouncements or changes in our accounting policies
4. 04We have no products approved for commercial sale and have not generated any revenue from product sales
5. 05maintain a continued acceptable safety profile of our products following approval
6. 06Our existing and any future indebtedness could adversely affect our ability to operate our business
7. 07We may need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts
8. 08obtaining and maintaining third-party insurance coverage and adequate reimbursement for any approved productsNew
9. 09Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates

Risks Related to the Discovery and Development of Our Product Candidates

1. 10We have not yet progressed any product candidates through a Phase 3 clinical trial and may be unable to successfully complete any additional clinical trials for any product candidates we develop. Certain of our programs are still in preclinical development and may never advance to clinical development31% rewritten
2. 11Our programs are focused on the development of therapeutics for patients with hematologic diseases, which is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates is novel and may never lead to approved or marketable products
3. 12Clinical development involves a lengthy and expensive process, with an uncertain outcome21% rewritten
4. 13Interim, top-line, initial and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data
5. 14We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our product candidates
6. 15regulators may revise the requirements for approving our product candidates, or such requirements may not be as anticipated
7. 16If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented73% rewritten
8. 17needed to provide appropriate statistical power for a given trial. In particular, because we are focused on patients with specific rare hematologic diseases for the development of our product candidates, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipateNew
9. 18In addition, some of our competitors have ongoing clinical trials for product candidates that are intended to treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may choose instead to enroll in clinical trials of our competitors’ product candidates
10. 19factors we may not be able to control, including the impacts of any public health crises, that may limit patients, principal investigators or staff or clinical site availability30% rewritten
11. 20Our clinical trials or those of our future collaborators may reveal significant adverse events not seen in prior preclinical studies or clinical trials and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates
12. 21Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval or discovery of unknown or unanticipated adverse effects on safety or efficacy
13. 22We have conducted and are currently conducting clinical trials for bitopertin, and may in the future conduct additional clinical trials of our product candidates, outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials
14. 23it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio
15. 24If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for any of our product candidates, we will not be able to commercialize, or will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired
16. 25the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval100% rewritten
17. 26protoporphyria. As a result, the FDA did not approve our NDA and indicated instead that we would need to provide evidence of a clinical benefit from an additional clinical trial, such as our ongoing APOLLO trial, to support a potential traditional approvalNew
18. 27A public health crisis, pandemic, epidemic, or outbreak of an infectious or highly contagious disease, may materially and adversely affect our business and financial results and could cause a disruption to the development of our product candidates

Risks Related to Commercialization

1. 28We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
2. 29If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability could be materially adversely affected27% rewritten
3. 30If our current product candidates or any future product candidates do not achieve broad market acceptance, the revenue that we generate from our sales may be limited, and we may never become profitable
4. 31potential product liability claims
5. 32We may not be successful in addressing these or other factors that might affect the market acceptance of our product candidates. Failure to achieve widespread market acceptance of our product candidates would materially harm our business, financial condition and results of operations
6. 33injunctions or the imposition of civil or criminal penalties
7. 34Product liability lawsuits brought against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may developNew
8. 35the inability to commercialize our product candidatesNew

Risks Related to Our Reliance on Third Parties

1. 36clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctionsNew
2. 37form relationships with other entities, some of which may be our competitors75% rewritten
3. 38We might not realize the anticipated benefits of our current collaborations with Mabwell or NIH, or any other collaborations we enter into in the future
4. 39collaborations might be terminated, which could result in a need for additional capital to pursue further research, development and/or commercialization of our product candidates
5. 40We have established collaborations with Mabwell and NIH and may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans98% rewritten
6. 41Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of CDMOs that operate under cGMP regulations and that might be capable of manufacturing for us37% rewritten
7. 42The third parties upon whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole sources of supply, and the loss of any of these suppliers could significantly harm our business27% rewritten
8. 43If any third-party manufacturer of any of our product candidates is unable to increase the scale of its production of such product candidates or increase the product yield of its manufacturing, then our costs to manufacture such product or product candidate may increase and any commercialization may be delayedNew

Risks Related to Our Intellectual Property

1. 44If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed43% rewritten
2. 45We may initiate, become a defendant in or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful
3. 46Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities27% rewritten
4. 47there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock
5. 48We may not obtain licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties
6. 49If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
7. 50the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners
8. 51Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates
9. 52We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates
10. 53Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks Related to Government Regulation

1. 54Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
2. 55We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process20% rewritten
3. 56We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
4. 57We have received rare pediatric disease designation for bitopertin. However, a marketing application for bitopertin, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher68% rewritten
5. 58Under current law, after September 30, 2029, the FDA may not award any rare pediatric disease priority review vouchers. However, it is possible that the FDA's authority to do so may be extended by Congress in the future23% rewritten
6. 59We received a Commissioner’s National Priority Voucher for bitopertin but the accelerated timeline for review of our NDA submission for bitopertin in EPP and XLP by the FDA did not result in an approval and it is unclear what, if any, benefits this voucher may provide in the futureNew
7. 60with the sponsor to clarify questions, and completing review of the application concurrently. Following completion of these steps, the multidisciplinary team will convene for a one-day “tumor board style” decision meetingNew
8. 61If our drug product candidates or any of our future drug product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of our competing products
9. 62If approved, our investigational products regulated as biologics may face competition from biosimilars or interchangeable products approved through an abbreviated regulatory pathway
10. 63The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict
11. 64The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses49% rewritten
12. 65levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a resultNew
13. 66Current and future healthcare reform measures may have a material adverse effect on our business and results of operations90% rewritten
14. 67downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability
15. 68federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products
16. 69increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry
17. 70If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business40% rewritten
18. 71remain free flowing. The UK Government introduced the Data Protection and Digital Information Bill, which failed in the UK legislative processNew
19. 72quality, transparency, and human oversight, as well as adhering to specific and potentially burdensome and costly ethical, accountability, and administrative requirementsNew
20. 73Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs

Risks Related to Employee Matters and Managing Growth

1. 74Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain, and motivate qualified personnel70% rewritten
2. 75We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations32% rewritten
3. 76could involve financial institutions or financial services industry companies with which the Company has financial or business relationships, but could also include factors involving financial markets or the financial services industry generallyNew
4. 77Changes in tax law may adversely affect us or our investors57% rewritten
5. 78Our future taxable income may be subject to certain limitations
6. 79Significant political, trade or regulatory developments, unfavorable global economic conditions, and other circumstances beyond our control, could have a material adverse effect on our business, financial condition or results of operationsNew
7. 80Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements or insider trading
8. 81The market price of our common stock has been, and may continue to be, volatile35% rewritten
9. 82period-to-period fluctuations in our financial results
10. 83We have incurred and will continue to incur increased costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies32% rewritten
11. 84were no changes to previously released financial results, our management concluded that these control deficiencies constituted a material weakness and that our internal control over financial reporting was not effective as of December 31, 2024New
12. 85Provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may discourage any takeover attempts our stockholders may consider favorable, and may lead to entrenchment of management
13. 86In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial
14. 87We do not anticipate that we will pay any cash dividends in the foreseeable future
15. 88Sales of a significant number of shares by existing stockholders could cause our stock price to decline44% rewritten
16. 89Our executive officers, directors and principal stockholders have the ability to significantly influence all matters submitted to our stockholders for approval31% rewritten
17. 90If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline